AlveoGene
A biotech start-up aiming to leverage a proprietary lentiviral gene therapy platform designed and developed by GTC specifically for inhaled delivery.
AlveoGene will use lentiviral vector technology and explore its application in other diseases, principally involving the lungs. The company's first target will be alpha-1 antitrypsin deficiency, a condition caused when a faulty gene fails to produce a protein that protects the lungs from damage when the body’s immune system is triggered to fight an infection or by irritants.
Latest AlveoGene News & Features
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze